Figitumumab is a monoclonal antibody that targets the insulin-like growth factor type I receptor (IGF1R). Figitumumab binds to IGF1R, resulting in a reduction in receptor expression on tumor cells that express IGF1R and inhibition of tumor growth.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.